InTrack Investment Management Inc Takes Position in Novo Nordisk A/S $NVO

InTrack Investment Management Inc bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,731 shares of the company's stock, valued at approximately $465,000.

Several other large investors have also recently modified their holdings of NVO. Notis McConarty Edward increased its stake in Novo Nordisk A/S by 329.7% in the second quarter. Notis McConarty Edward now owns 18,950 shares of the company's stock worth $1,308,000 after purchasing an additional 14,540 shares during the period. Capital Management Associates Inc purchased a new stake in Novo Nordisk A/S in the second quarter worth $373,000. Dempze Nancy E increased its stake in Novo Nordisk A/S by 64.3% in the second quarter. Dempze Nancy E now owns 14,678 shares of the company's stock worth $1,013,000 after purchasing an additional 5,743 shares during the period. Guild Investment Management Inc. increased its stake in Novo Nordisk A/S by 20.7% in the second quarter. Guild Investment Management Inc. now owns 36,995 shares of the company's stock worth $2,553,000 after purchasing an additional 6,345 shares during the period. Finally, Puzo Michael J increased its stake in Novo Nordisk A/S by 79.0% in the second quarter. Puzo Michael J now owns 43,933 shares of the company's stock worth $3,032,000 after purchasing an additional 19,383 shares during the period. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. UBS Group lowered Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Dbs Bank upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, August 22nd. Morgan Stanley lowered Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and reduced their target price for the stock from $59.00 to $47.00 in a research note on Monday, September 29th. Finally, Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.50.

Novo Nordisk A/S Trading Up 1.0%

Novo Nordisk A/S stock opened at $59.63 on Thursday. The stock has a 50-day moving average of $55.03 and a two-hundred day moving average of $63.45. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56. The stock has a market cap of $266.25 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 2.64 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.